Login
Israel-Hamas Conflict
Independence Day
Social Media
Donald Trump
Artificial Intelligence
Heatwaves
European Union
Soccer
Taxes
Netflix
Fire
Music
Infrastructure
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

Summary by biopharmadive.com
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound.

1 Articles

All
Left
Center
1
Right
biopharmadive.combiopharmadive.com
Center

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Tuesday, June 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

23andMe icon

23andMe

United States icon

United States

You have read 1 out of your 5 free daily articles.

News
For You
SearchBlindspotLocal